Biokine Therapeutics
Anticancer and Stem Cell Mobilization Drugs
StartupBiokine Therapeutics is a Rehovot-based startup in the Health Tech & Life Sciences sector, established in 2000. Anticancer and Stem Cell Mobilization Drugs. The company has raised a total of $1.95M across 2 funding rounds, currently at the Mature stage. Biokine Therapeutics was founded by Amnon Peled, Prof.. Key investors include Clal Biotechnology Industries (CBI), Amnon Peled. The company has 1-10 employees. Core technologies: Biologicals, Cells.
With $1.95M in total funding, Biokine Therapeutics is a Mature-stage company operating in Health Tech & Life Sciences. The company follows a B2C business model. Product stage: Released.
- StageMature
- ProductReleased
- ModelB2C
- Employees1-10
- HQRehovot
- DistrictCenter District
- Last Round$1.2M
- Clal Biotechnology Industries (CBI)
- Amnon Peled
Amnon Peled, Prof.CEO/CSO and Founder
6 articles covered by sources including ir.biolinerx.com,
biokine.com,
www.globes.co.il.
What does Biokine Therapeutics do?
Biokine Therapeutics is a clinical-stage biopharmaceutical company developing novel drugs to treat cancer. Founded in 2000 by Prof. Amnon Peled, a leading cancer and stem cell biologist at Hadassah University Hospital, Biokine has completed many years of R&D and clinical research. The company is devoted to identifying novel molecular and cellular mechanisms that regulate tumor development and metastasis. Biokine has developed a suite of unique approaches to target cancer and is conducting preclinical and clinical research on several molecules discovered and developed in-house. The companys lead drug candidate, the high-affinity CXCR4 antagonist BKT140/BL8040, is currently in a phase 2a clinical trial for the treatment of refractory and relapsed acute myeloid leukemia (AML), as well as a phase 1 clinical trial for the mobilization of stem cells. The CXCR4 receptor plays a pivotal role in the regulation of certain cancers and inflammatory diseases and is critically involved in stem cell biology and tissue regeneration. BKT140/BL8040 was licensed to BioLineRx Ltd.
How much funding has Biokine Therapeutics raised?
Biokine Therapeutics has raised $1.95M in total funding across 2 rounds. The company is currently at the Mature stage. Key investors include Clal Biotechnology Industries (CBI), Amnon Peled.
Who founded Biokine Therapeutics?
Biokine Therapeutics was founded in 2000 by Amnon Peled, Prof. (CEO/CSO and Founder).
What sector is Biokine Therapeutics in?
Biokine Therapeutics operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals, Cells. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals, Healthcare, Patients, Providers.
Where is Biokine Therapeutics located?
Biokine Therapeutics is based in Rehovot, Israel, Center District.